Glass Delamination Studies for Pharmaceutical Containers

Glass delamination studies for pharmaceutical containers according to USP <1660> including screening analysis, studies of lamellae formation & data assessment

Glass delamination studies for pharmaceutical containers are necessary to mitigate risks associated with generation of lamellae (or small glass flakes) from the inner surface of a glass pharmaceutical container.

Glass delamination represents a serious quality issue, and several drugs have recently been recalled due to this problem and Regulatory Authorities such as the US Food and Drug Administration (FDA) have highlighted these product recalls. Small glass particles - when injected directly into a patient - may lead to serious health risks such as embolic, thrombotic and other vascular events.

Manufacturing process differences within the glass industry and the nature of drug product are reported to be the most dominant factors that enhance glass delamination. Manufacturing conditions such as the moulding process or formation from glass tubing under high temperatures, plus any additional treatments after formation, storage conditions and duration of storage processing operations at the pharmaceutical manufacturer (such as terminal sterilization by autoclaving) can all reduce the chemical resistance of glass. Various interactions can arise when products come in contact with glass surfaces including leaching, ion exchange, precipitation, glass dissolution and more.

Our glass delamination specialists provide a range of solutions that help mitigate the risks associated with glass delamination for moulded bottles, containers, vials or prefillable syringes. We provide laboratory services according to United States Pharmacopeia (USP) Chapter <1660>, ‘Evaluation of the Inner Surface Durability of Glass Containers’ to monitor ‘early stage’ indicators through predictive  screening studies which begin with an assessment of the glass materials by applying the Surface Glass Test 660 (Type 1 glass). We then use aggressive screening conditions via a series of accelerated temperatures to establish the chemical durability of the container. This can help you to select the most chemically durable glass or determine if changes in glass quality have occurred.

We also study the potential for lamellae formation with programs conducted over a suitable period of time with storage at elevated temperature conditions to stress the system.

Our expertise helps you to ensure that patient safety and product quality are not compromised when a glass vial, cartridge, or syringe are used as primary packaging for your pharmaceutical product. Intertek thought-leaders have over 20 years’ experience with pharmaceutical packaging materials, container closure systems and product development support and can assist you in minimising the risks associated with glass delamination. Our teams can also assist you in detailed studies of potential contamination by glass packaging beyond glass delamination, including the study of metal ions leaching from glass, interaction with buffers and adsorption of drug(s) or formulation components on glass surfaces.

 

Our laboratories monitor the pH and the extracted elements in solution, in particular determining the concentration of silicon using inductively coupled plasma-optical emission spectroscopy (ICP-OES) or ICP-mass spectrometry techniques (ICP-MS). The presence of a higher amount of glass ions (e.g. Si, Al, B) in the test solutions is indicative of loss of glass durability or onset of glass delamination which may lead to formation of particulate matter or glass flakes.

We can conduct these studies with model systems but can also perform with the drug product liquid stored in the glass container. This helps to assess the propensity of a pharmaceutical liquid to react with its primary glass container.

Lamellae, due to their size, are difficult to detect by visual inspection. However, by using specialist microscopy techniques, we can perform tests to confirm product and glass quality. Our experts deploy light microscopy, followed by scanning electron microscopy (SEM) to inspect the size, shape and morphology of even sub visible particles that could have been released from the inner vial surface – a typical indication of delamination. Further examination into the nature of the particles is achieved with SEM - combined with energy-dispersive X-ray spectroscopy (EDX) to determine the elemental composition of detected particles and their origin.

SEM can also provide direct evidence that the glass and the liquid product are interacting by studying the appearance of inner vial surfaces. This data, together with high contrast detection microscopy studies using differential interference contrast (DIC), can reveal a detailed picture of pitting and corrosion of the interior surface of a vial.

Need help or have a question? +1 800 967 5352
 

Need help or have a question?

+1 800 967 5352
EMEA UK:
+44 161 721 5247
Switzerland:
+41 61 686 4800
 
 
 
 
 

Explore Our Pharmaceutical Services

Intertek Pharmaceutical Brochure 2017
Custom Extractables and Leachables Solutions Brochure